TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan
TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ("Orient EuroPharma"; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marki
TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ("Orient EuroPharma"; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking the final step toward the commercial launch of Trogarzo in Taiwan.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.